Labelled leucocyte imaging is an established technique for the detection of inflammation and sepsis. Of the many radioisotopes used to label leucocytes, Indium-l1 tropolonate (11 1In) and Technetium-99m hexamethyl propylene amine oxime (99mTc HMPAO) are the most widely used. Leucocytes are obtained from heparinised, peripheral venous blood (40-100 ml) and then separated from erythrocytes and platelets by sedimentation with hydroxyethyl starch. Cell labelling is achieved by incubation with the radioisotope in plasma (or saline). After washing, the labelled leucocytes are injected intravenously and serial images are obtained using a gamma camera. ' In labels and remains firmly bound to all cells in mixed leucocyte suspensions. The use of pure granulocyte preparations probably reduces background activity and improves the image quality.' 99mTc HMPAO initially binds to all blood cells but subsequently elutes from platelets and red cells leaving labelled granulocytes behind. 99mTc HMPAO is therefore considered a selective granulocyte label even when mixed leucocyte preparations are used.2 3 After injection, the labelled granulocytes marginate and then migrate into the inflamed lesion before being shed into the bowel lumen.
Serial imaging is important to distinguish luminal from bowel wall activity. With "'In images are most often obtained at three to four hours.4 Forward migration of luminal radioactivity5 makes late (24 hours) scans of little value, except when the technique is used to detect sepsis, for which late imaging is required. After 99mTc HMPAO imaging at 14 24 28 colonoscopy,13 21 20 22 26 28 29 Leading articles express the views of the author and not those of the editor and the editorial board.
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When the aim of labelled leucocyte bowel imaging is to detect active colonic inflammation regardless of its precise location, the technique has a sensitivity, specificity, and diagnostic accuracy of 650/6-100%, 50°/o-100%, and 370/695% respectively compared with endoscopy and radiology. 15 17 20 23-25 27 [30] [31] [32] [33] Differences between studies in the proportion of patients with active disease are a major factor in determining the wide variations in the reported sensitivity and accuracy of "'In scanning. Similar results have been reported with 99mTc HMPAO, although identification of various bowel segments is improved because of better image quality. [25] [26] [27] [28] [29] The role of labelled leucocyte imaging in the evaluation of small bowel disease is uncertain. Many studies have shown that "'In labelled leucocyte scanning has a sensitivity of 70% compared with small bowel radiology.'7 30 When used to assess small bowel disease, "1'In has a high false negative rate which reduces its diagnostic accuracy.17 30 Although negative "1'In scans are often obtained from patients with inactive disease, there are worrying reports of negative scans in patients with unequivocally active small bowel inflammation. ' Labelled leucocyte bowel scintigraphy in inflammatory bowel disease is of particular value in assessing disease activity. Two methods have been described for the quantification of the abnormal bowel uptake on the gamma camera scans -a simple visual grading system whereby the intensity of bowel activity is compared with that of bone marrow, liver, and spleen'3 16 183233 and, secondly, more detailed computer based methods with or without background subtraction. 24 43 Bowel uptake, whether quantified by visual or computer methods, has been shown to correlate with clinical indices'2 16 25 Labelled leucocyte scintigraphy is particularly useful in the management of patients with Crohn's disease who present with symptoms of small intestinal obstruction. Bowel imaging enables the differentiation of obstruction due to an inflammatory stricture, when medical treatment will be appropriate, from that due to fibrous stricture when surgical intervention will be required.70
Screening for inflammatory bowel disease Abdominal pain and altered bowel habits constitute over 40% of all referrals to gastroenterology clinics. Up to 60% of these patients have functional bowel disorders but because of considerable overlap in clinical and laboratory features a rigorous approach is often needed before inflammatory bowel disease can be confidently excluded. This may entail detailed radiological and endoscopic assessment.7' Labelled leucocyte scintigraphy has been used as a screening test in patients with suspected irritable bowel syndrome.50 72 73 False negative images are the main problem with 1 "'In scanning. Although this is rarely seen in symptomatic patients with active disease, it significantly reduces the diagnostic accuracy of the technique. Studies which included patients with chronic diarrhoea due to the irritable bowel syndrome as controls have shown low false positive rates with "llIn granulocyte imaging and FIE. 72 Saverymuttu et al 72 have shown that 1"'In labelled leucocyte scanning is better than bowel radiology and rectal histology when used as a screening test for inflammatory bowel disease. 99mTc HMPAO seems to be as sensitive as 1"'In for the detection of active inflammation but appears to have high false positive rate in patients with no evidence of inflammatory bowel disease. 73 Gibson et al 73 recently questioned the diagnostic value of a positive 99mTc HMPAO scan in predicting intestinal inflammation in patients with a low probability of inflammatory bowel disease.
Thus the value of labelled leucocyte scanning as a screening test in patients suspected of having inflammatory bowel disease remains to be established. When used for this purpose 99mTc HMPAO is preferable because it is more sensitive for small bowel disease and produces better quality images. A negative 99mTc HMPAO scan in symptomatic patients virtually excludes inflammatory bowel disease, while a strongly positive scan makes such a diagnosis likely. A few patients, mostly those with irritable bowel syndrome, may have 'slightly' positive scans in these diagnosis cannot be made from the scan appearance.
"'In or 99mTc HMPAO? Stable labelling of granulocytes can be achieved with either "'In or 99mTc HMPAO, with comparable labelling efficiency and granulocyte recovery times.7480 Whole body distribution of the two tracers is similar with early locations to bone marrow, liver, and spleen. Significant renal, biliary, and non-specific bowel excretion of noncellular bound 99mTc labelled hydrophillic complexes is frequently seen with 99mTc HMPAO, particularly on late images.76 77 79 81 Although this may make scan interpretation difficult, it can be circumvented by early (one hour) and serial imaging. The short half life of 99mTc HMPAO together with biliary excretion make faecal excretion studies impractical. Disease activity and extent must therefore be estimated from the abdominal images. 99.mTc is, however, readily available and because of its physical characteristics is more suited to the gamma camera, producing images of superior quality. Granulocytes can selectively be labelled with 99mTc HMPAO in mixed leucocyte suspensions, obviating the need for granulocyte separation, a tedious and time consuming step. Radiation dosimetry is higher with "'In than with 99mTc. The effective dose equivalent as follows: 12 mSv for "1'In scans (20 MBq), 3.4 mSv for 99mTc HMPAO scans (200 MBq), 7.7 mSv for barium enema, and 7.4 mSv for small bowel enema. The uterine and splenic absorbed dose is also higher with "'1In (2 mGy and 56 mGy respectively) than 99mTc HMPAO (0.8 mGy and 31.3 mGy respectively). 74 In the clinical setting 99mTc HMPAO labelled leucocytes are as useful as those labelled with "'In. Except when faecal excretion studies are contemplated, 99mTc
HMPAO should be the preferred leucocyte label, on the grounds of availability, image quality, ease of use, and radiation dosimetry. 
